ExonHit predicts 2009 US/EU filings for approval of AD (Alzheimer's disease) blood test:
This article was originally published in Clinica
ExonHit Therapeutics is aiming to apply for the approval of its Alzheimer's disease (AD) blood test in both Europe and the US in 2009. So far, the multigene expression test has been shown to distinguish those with AD from those that have no cognitive impairment. In upcoming studies, the Paris, France firm hopes to prove that the test can differentiate AD from other brain pathologies, such as front temporal dementia, vascular dementia, Parkinson's disease, and also reversible dementias. Initially, the company hopes to market its test in Europe to pharma companies, for use in drug development. Following this, it plans to license the commercial rights to the test to one or more in vitro diagnostic companies. ExonHit claims that some 28 million people suffer from AD worldwide.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.